Digital Health & Medical Technology · medium ·
Clinical testing specialists target digital biomarker developers with bias stress tests for tougher premarket reviews
Global drug and device regulators are actively shifting from high-level ethical frameworks to strict, evidence-based validation mandates for software and generative models. With the FDA demanding clinical utility proof for digitally derived endpoints and the MHRA tightening sandbox protocols, digital health developers face steep compliance barriers. Software builders lacking structured regulatory stress-testing environments risk multi-year approval delays.
Part of the Healthcare & Life Sciences Opportunity Outlook, Korim's monthly analysis of emerging opportunities in this sector.